加载中
COMPASS Pathways plc is a mental healthcare company with a primary presence in the United Kingdom and the United States. Established in 2020 and headquartered in London, UK, the firm focuses on developing novel treatments. Its key product is COMP360, an investigational psilocybin therapy. This therapy has advanced through Phase IIb clinical trials for treatment-resistant depression and is currently undergoing Phase II trials for post-traumatic stress disorder. The company previously operated under the name COMPASS Rx Limited before rebranding to COMPASS Pathways plc in August 2020.
前收盘价
US$11.53
−US$0.47 · -3.92%
盘前
US$11.70
+US$0.17 · +1.47%
10月13日 4:00 ET
盘中时间采用ET。市场数据可能有所延迟。
COMPASS Pathways plc is a mental healthcare company with a primary presence in the United Kingdom and the United States. Established in 2020 and headquartered in London, UK, the firm focuses on developing novel treatments. Its key product is COMP360, an investigational psilocybin therapy. This therapy has advanced through Phase IIb clinical trials for treatment-resistant depression and is currently undergoing Phase II trials for post-traumatic stress disorder. The company previously operated under the name COMPASS Rx Limited before rebranding to COMPASS Pathways plc in August 2020.
日内区间
当前US$11.53
52周区间
当前US$11.53
盘中时间采用ET。市场数据可能有所延迟。
COMPASS Pathways plc is a mental healthcare company with a primary presence in the United Kingdom and the United States. Established in 2020 and headquartered in London, UK, the firm focuses on developing novel treatments. Its key product is COMP360, an investigational psilocybin therapy. This therapy has advanced through Phase IIb clinical trials for treatment-resistant depression and is currently undergoing Phase II trials for post-traumatic stress disorder. The company previously operated under the name COMPASS Rx Limited before rebranding to COMPASS Pathways plc in August 2020.
日内区间
当前US$11.53
52周区间
当前US$11.53
营业利润
净利润
| 项目（USD） | 2025财年 | 2024财年 | 2023财年 | 2022财年 | 2021财年 |
|---|---|---|---|---|---|
| 研究与开发 | 1.18亿 USD | 1.19亿 USD | 8751.8万 USD | 6505.3万 USD | 4402.7万 USD |
| 销售、一般及管理费用 | 6060.1万 USD | 5916.6万 USD | 4940.1万 USD | 4535万 USD | 3919.4万 USD |
| 营业费用 | 1.79亿 USD | 1.78亿 USD | 1.37亿 USD | 1.1亿 USD | 8322.1万 USD |
| 利息收入 | 718.2万 USD | 826.8万 USD | 462.3万 USD | — | — |
| 利息支出 | 451.7万 USD | 447.9万 USD | 220.4万 USD | — | — |
| 折旧和摊销 | 21.6万 USD | 23.3万 USD | 24.2万 USD | 33万 USD | 17.5万 USD |
| 营业利润 | −1.79亿 USD | −1.78亿 USD | −1.37亿 USD | −1.1亿 USD | −8322.1万 USD |
| 净利润 | −2.88亿 USD | −1.55亿 USD | −1.18亿 USD | −9150.5万 USD | −7174.2万 USD |
公司数据更新于 2026年10月13日。
近期已公布业绩
第三方分析师预期可能变化，并非 GoAI 建议。
报告持有此股票敞口的交易所交易基金。
ARK Genomic Revolution ETFARKG5642.65万2.74%22.19亿 USD0.75%US$49.48-3.55%
iShares Biotechnology ETFIBB1058.97万0.10%108.2亿 USD0.44%US$204.26-1.08%
AdvisorShares Psychedelics ETFPSIL517万11.30%4574.2万 USD1.84%US$21.26-2.32%
ALPS Medical Breakthroughs ETFSBIO202.78万1.08%1.87亿 USD0.50%US$53.85-2.16%
T. Rowe Price Small-Mid Cap ETFTMSL161.36万0.05%30.87亿 USD0.55%US$40.99-0.46%
State Street SPDR S&P International Small Cap ETFGWX116.88万0.13%9.15亿 USD0.40%US$45.26-0.66%
ROBO Global Healthcare Technology and Innovation ETFHTEC105.67万0.98%1.08亿 USD0.80%US$43.00-0.07%
Simplify Propel Opportunities ETFSURI104.21万1.38%7606.44万 USD2.82%US$17.2565+0.23%ARK Genomic Revolution ETFARKGiShares Biotechnology ETFIBBAdvisorShares Psychedelics ETFPSILALPS Medical Breakthroughs ETFSBIOT. Rowe Price Small-Mid Cap ETFTMSLState Street SPDR S&P International Small Cap ETFGWXROBO Global Healthcare Technology and Innovation ETFHTECSimplify Propel Opportunities ETFSURIAI 生成内容及延迟市场数据仅供信息与教育用途，不构成投资建议。
